Last reviewed · How we verify
NCT05930314
CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus
EARLY_PHASE1 trial testing CNCT19 cell injection in Refractory Systemic Lupus Erythematosus in 12 participants. Status unknown.
30 May 2024
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 19 June 2023 |
| Primary completion | 30 May 2024 |
| Estimated completion | 30 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- CNCT19 cell injection — full drug profile →
Conditions studied
- Refractory Systemic Lupus Erythematosus — all drugs for Refractory Systemic Lupus Erythematosus →
- Lupus Nephritis — all drugs for Lupus Nephritis →
- Immune Thrombocytopenia — all drugs for Immune Thrombocytopenia →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 70, any sex, with Refractory Systemic Lupus Erythematosus or Lupus Nephritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB, Brudno JN, Borie D, Kochenderfer JN. · · 2024 · cited 85× · PMID 38831163 · DOI 10.1038/s41577-024-01035-3 -
CAR T cells for treating autoimmune diseases.
Blache U, Tretbar S, Koehl U, Mougiakakos D, et al · · 2023 · cited 54× · PMID 37996128 · DOI 10.1136/rmdopen-2022-002907 -
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.
Zhou J, Lei B, Shi F, Luo X, et al · · 2024 · cited 26× · PMID 39749335 · DOI 10.3389/fimmu.2024.1476859 -
Cutting-edge approaches to B-cell depletion in autoimmune diseases.
Robinson WH, Fiorentino D, Chung L, Moreland LW, et al · · 2024 · cited 24× · PMID 39445025 · DOI 10.3389/fimmu.2024.1454747 -
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
Shah K, Leandro M, Cragg M, Kollert F, et al · · 2024 · cited 23× · PMID 38642912 · DOI 10.1093/cei/uxae031 -
Current cell therapies for systemic lupus erythematosus.
Dao LTM, Vu TT, Nguyen QT, Hoang VT, et al · · 2024 · cited 16× · PMID 38920310 · DOI 10.1093/stcltm/szae044 -
Current advancements in cellular immunotherapy for autoimmune disease.
Berry CT, Frazee CS, Herman PJ, Chen S, et al · · 2025 · cited 15× · PMID 39821376 · DOI 10.1007/s00281-024-01034-5 -
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
Lyu X, Gupta L, Tholouli E, Chinoy H. · · 2024 · cited 15× · PMID 37982747 · DOI 10.1093/rheumatology/kead616
Verify or expand the search:
- PubMed search for NCT05930314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CNCT19 cell injection
Trials testing the same drug.
- NCT07275736 — A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases · EARLY_PHASE1 · recruiting
Other recruiting trials for Refractory Systemic Lupus Erythematosus
Currently open trials in the same condition.
- NCT06676631 — NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis · Phase 1 · recruiting
- NCT06530849 — A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus · Phase 1, PHASE2 · recruiting
- NCT06513429 — IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) · NA · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05930314 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 5 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing